Peptide & Experimental
PRL-8-53
Synthetic phenethylamine derivative (benzoic acid ester), nootropic from the 1970s, approved nowhere · Methyl 3-(2-(benzylmethylamino)ethyl)benzoate, 3-(2-benzylmethylaminoethyl)benzoic acid methyl ester (hydrochloride)
PRL-8-53 is a curiosity among nootropics: a small molecule from the 1970s that improved the retention of word lists in a double-blind study in humans. This study should be taken seriously. But it has stood alone since 1978, and much of what is said about it today goes far beyond it.
In short
PRL-8-53 is a synthetic derivative of phenethylamine, developed by the chemist Nikolaus Hansl at Creighton University in Omaha. In a placebo-controlled double-blind study from 1978, test subjects learned word lists somewhat faster under the substance and retained them statistically significantly better, without any change in reaction time or motor skills. That is the entire human evidence: one study, by the inventor himself, never repeated, with the full text available only for a fee. Approval, long-term data and a clarified mechanism of action are lacking. In Germany, according to the wording of the New Psychoactive Substances Act, the substance falls under a prohibited substance group.
What it is
Chemically, PRL-8-53 is the methyl ester of a benzoic acid to whose ring an aminoethyl chain with a methyl and a benzyl group on the nitrogen is attached. This places the molecule in the large family of phenethylamine derivatives. It is not a peptide, even though some vendors list it as such. In the lab it was mostly used as the hydrochloride salt.
The story begins in the early 1970s. In 1973 Hansl filed a patent on a whole series of related benzoic acid esters, which was granted in 1975 as US 3,870,715. It claims the substances as antispasmodics, as psychotherapeutic agents and as agents that facilitate learning. The patent expired long ago.
In 1974 Hansl first described the compound in the journal Experientia. He called it a new type of substance activating the central nervous system with a specific effect on the learning process and memory and at the same time a marked antispasmodic effect. His places of work are given there as Creighton University and the Pacific Research Laboratories in Santa Barbara.
How it is supposed to work
How PRL-8-53 works remains unclear to this day. The patent describes the substance group as cholinergic, that is, related to the messenger acetylcholine, which is important for learning and memory, and as antispasmodic. The antispasmodic effect was measured on isolated rabbit intestine and compared with the classic papaverine.
For the memory effect, the patent refers to experiments in rats. In avoidance tests and in maze tests with water as a reward, the animals are said to have learned faster under the substance and retained what they had learned better. Raw data on this have not been published; these are the inventor’s statements.
Online one often reads that PRL-8-53 enhances dopamine and dampens serotonin. We have found no accessible primary source for these statements. They may come from the full text of the original papers, but cannot be verified.
What the scene makes of it
PRL-8-53 has a firm place in the nootropics scene. An analysis of psychonaut forums using a web crawler found a total of 142 cognitive enhancers discussed there in 2020; PRL-8-53 was one of them. The forums describe it as a research chemical from the 1970s for which a single study shows a drastic improvement in medium-term memory, but about which little else is known; it has no potential for intoxication. That is a scene report, not a measurement.
Three narratives are particularly persistent. First: PRL-8-53 doubles memory. The percentages cited for this come from the paywalled 1978 full text and cannot be verified without it; the freely accessible abstract speaks of slightly improved learning and significantly better retention. Second: the effect has been confirmed many times. There is exactly one human study. Third: PRL-8-53 is a peptide. It is a small, lab-built molecule.
What is well supported
The strongest thing PRL-8-53 can show is a genuine human study with a design that is remarkably clean for the 1970s: double-blind, with placebo as comparison. PubMed lists it as a controlled, randomized trial. Measurement used the serial anticipation method, in which one learns word lists and has to predict the next word in each case. Under PRL-8-53 the test subjects learned somewhat faster, and they retained the lists statistically significantly better, mostly with p-values below 0.01, sometimes below 0.001.
What did not change is interesting. Visual reaction time and motor skills did not differ from placebo. This argues against a general stimulating effect of the kind known from stimulants and fits a rather memory-specific effect. In addition, there are the animal experiments described in the patent with better learning in rats and a toxicity described by the inventor as low.
What the studies show
Hansl and Mead, Psychopharmacology 1978
The only human study. Double-blind against placebo; the learning and retention of verbal lists was measured, along with reaction time and motor skills. Result according to the abstract: slightly improved acquisition, significantly better retention, no change in reaction time and motor skills. Number of participants, study duration and effect sizes are only in the full text, which is not freely accessible. According to Europe PMC, the paper has been cited twice since then.
Hansl, Experientia 1974
The first description on two journal pages. Hansl presents the compound as a new type of substance activating the central nervous system, with a specific effect on learning and memory and a pronounced antispasmodic effect. There is no abstract with figures.
Patent US 3,870,715 (1975)
The most detailed freely readable source. It describes intestinal experiments in rabbits, learning and memory tests in rats and toxicity tests in mice, rats, dogs and monkeys, including reproduction studies over two generations of offspring without malformations. All statements come from the inventor and have not been independently published.
Where the data stop
The central limitation is simple: one study. It dates from 1978, was conducted by the inventor himself and, as far as could be found, has never been repeated by another group. There is not a single entry in the trial registry ClinicalTrials.gov. How many people took part, how large the effect was in everyday life and which side effects occurred cannot be verified without the paywalled full text. We therefore do not adopt the percentages circulating in forums and vendor texts.
In other respects too, the list of open questions is long. The mechanism of action is unclear, there are no published data on absorption and residence time in the body, and none on interactions either. Whether PRL-8-53 works in older people, in memory disorders or over longer periods has never been studied. The animal and toxicity data exist only as a summary in the patent.
Status, approval and legal
PRL-8-53 is not approved as a medicine anywhere and in the EU is neither a food nor a food supplement. In Germany, the New Psychoactive Substances Act regulates entire substance groups instead of individual names. According to the wording of the group of compounds derived from 2-phenethylamine, as of January 7, 2026, PRL-8-53 meets the structural criteria: phenyl ring with a modified carboxy group, aminoethyl chain with methyl and benzyl on the nitrogen, molecular mass below 500 u. Trade, acquisition and possession would therefore be prohibited, except for recognized scientific purposes. We have not found an individual assessment by the authorities; this is a reading of the legal text, not legal advice. PRL-8-53 is not listed in the German Narcotics Act. In sport it is not on the World Anti-Doping Agency’s 2026 prohibited list by name; as a phenethylamine derivative, classification under the stimulants S6 is possible, otherwise S0 applies for non-approved substances. A 2025 analysis classifies the status as unclear.
Safety
There are no reliable safety data in humans. From the 1978 study it is only known that reaction time and motor skills remained unchanged. The patent describes low toxicity in mice, no malformations over two generations of offspring, no organ damage in rats after continuous administration and good tolerability in dogs and monkeys; these are the inventor’s statements without independent verification. There are no data whatsoever on interactions, on use during pregnancy and breastfeeding, or in children and adolescents. Products traded as research chemicals are untested for purity and content. Anyone who notices persistent problems with memory or concentration should have this checked by a doctor.
BK-Score Hype far ahead of evidence
| Human evidence | 3 | |
|---|---|---|
| Mechanism | 2 | |
| Safety data | 2 | |
| Hype gap | 3 | |
| Track record of use | 2 |
Evidence 3, because there is exactly one human study: double-blind and placebo-controlled, with significantly better retention of verbal lists (mostly p below 0.01, sometimes below 0.001) and unchanged reaction time and motor skills (Hansl & Mead 1978), but by the inventor himself, never repeated, without a registry entry at ClinicalTrials.gov and with sample size and effect sizes only in the paywalled full text. Mechanism 2, because apart from the classification as cholinergic and antispasmodic in the patent and a brief first description (Hansl 1974), nothing has been published; animal data on learning and retention exist only as a manufacturer’s statement. Safety 2, because toxicity data (mice, rats over two generations of offspring, dog, monkey) appear only in the patent and there is no systematic tolerability testing in humans. Hype 3, because the scene turns a single study into a doubling of memory and a repeatedly confirmed effect, and in some cases wrongly lists the substance as a peptide. Use 2, because PRL-8-53 was never introduced clinically and occurs only in studies and a niche of the gray market. Direction open, because the only finding is positive but does not hold up without replication.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about PRL-8-53
What is PRL-8-53?
PRL-8-53 is a synthetic phenethylamine derivative developed by the chemist Nikolaus Hansl in the 1970s. It was patented as an agent to promote learning and memory, but never came onto the market. Today it circulates in the nootropics scene as a research chemical.
Does PRL-8-53 really work on memory?
There is a double-blind, placebo-controlled study from 1978 in which word lists were retained significantly better under PRL-8-53. This study was never repeated, and its details are only in the paywalled full text. So an indication, but not proof.
Is PRL-8-53 a peptide?
No. PRL-8-53 is a small, lab-built molecule, chemically a benzoic acid methyl ester with a phenethylamine backbone. Its classification as a peptide by some vendors is wrong.
Why are there no newer studies on PRL-8-53?
After the papers of 1974 and 1978 no further studies have appeared, and why is not documented. An obvious reason: the patent has expired, so there is no property right that would make expensive studies worthwhile for a company. No study is registered in the trial registry ClinicalTrials.gov.
Is PRL-8-53 legal in Germany?
According to the wording of the German New Psychoactive Substances Act, PRL-8-53 falls under the prohibited substance group of phenethylamine derivatives. Trade, acquisition and possession would therefore be prohibited. We have not found an individual assessment by the authorities on this.
Does PRL-8-53 have side effects?
That has not been systematically studied. In the only human study, reaction time and motor skills remained unchanged; further information on tolerability is not freely accessible. The animal data on low toxicity come only from the inventor’s patent.
Related
- Related topicSunifiram
- Related topic9-Me-BC (9-Methyl-β-carboline)
- Related topicAdamax
- Related topicDrostanolone (Masteron)
- Same sectionNoopept
- Same sectionPhenylpiracetam (Phenotropil)
Sources
- Hansl and Mead, Psychopharmacology 1978 – PRL-8-53, learning and retention in humans
- Hansl, Experientia 1974 – first description as a spasmolytic, CNS-active compound
- Patent US 3,870,715 – Substituted amino ethyl meta benzoic acid esters (Hansl, 1975)
- PubChem – PRL-8-53, structure and substance data
- Napoletano et al., Frontiers in Psychiatry 2020 – cognitive enhancers in psychonaut forums
- Pokrywka et al., Biology of Sport 2025 – brain doping substances and the WADA list
- German New Psychoactive Substances Act (NpSG) with Annex 1 (substance groups)
- WADA Prohibited List 2026 (official promulgation, BGBl. III Nr. 219/2025)
- ClinicalTrials.gov – search for PRL-8-53
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-27.